Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aflao, where do you get your L2 from...thanks
"We have recently received a request for licensing our software for other providers, interest for merging with multiple companies and still have multiple marketing partners pending. We felt that it was important to still have a January CEO conference call and assure you that although our primary focus is generating new business, completing the financials is still a top priority for us,” continued Watson."
those are from
Guard Dog ID Review
September 7, 2010
Click on the guarddog link and you will go here
http://www.creditprotectionpro.com/credit-protection/guard-dog-id-review/
would appreciate it also Nobo...thanks
Great volume, nice up move, Friday could be great!
Plus 4 deals in the works
Plus increased revenues through the production of our own existing products
For purposes of consummating the Acquisition, PSP shall increase its authorized share capital to 200,000,000 shares prior to issuing shares in exchange for the interests of Seawind. Rudana Investment Group AG (“Rudana”), the majority shareholder of PSP, shall, prior to the closing of the Acquisition, contribute into the new PSP structure certain Hydro power projects described in the Term Sheet. At the closing of the Acquisition, Seawind shall tender all of the issued and outstanding shares of Seawind to PSP, and PSP shall issue to the owners of Seawind shares equal in amount to the number of shares owned by Rudana.
Awesome stuff...Chio, i can't find how many employees PSPW had/has (prior to all this)
and I believe it correct that Olivier de Vergnies and Barbara Salz were the only two officers..
Hi guys, new here, exciting stuff...Does anyone have an insight on the depressed share price. I read all the stickies and went to the website...Huge Evaluation! I would think this stock would be edging it's way north. Speaking of North ; ) ... I live only a few hours from Edmonton and if I can get comfortable enough to invest, I just might give the company a visit.
Thanks for any input.
Neuro-Biotech Corp. Releases a List of Answers Regarding Numerous Enquiries
Monday 22, November 2010
NEURO-BIOTECH CORP. RELEASES A LIST OF ANSWERS REGARDING NUMEROUS ENQUIRIES
BASEL, SWITZERLAND, Nov. 22 - Neuro-Biotech Corp. (OTCQB: MRES) publishes answers to the most frequently asked questions.
The topic commonly asked about is in regards to Company's statements that no further R&D needs to be carried out on the 16 products that have been licensed. This technical platform was bought from a university following 20 years of research for the sum of $3 million. A total of $5 million was spent by the end of 2000 and subsequently, in the last 10 years research and development has yielded 16 products that are ready for production.
Neuro-Biotech's first blood test, SymPath has been the subject of more than 5,000 clinical tests and 75,000 units were sold before its voluntary withdrawal from the market. The SymPath is currently the only blood test on the planet which can successfully measure on a scale, recognized by the World Health Organization, (similar to the scale that is used to measure cholesterol) the mental state of a patient and by analogy the physical consequences, thus allowing physicians to carry out a more precise diagnosis. It should also be mentioned that the eighth blood test of our portfolio NeuroChAT is currently the only blood test allowing an early diagnosis of Alzheimer's Disease.
The Company has stated in its financials such as its 10-Q, that it does not have any employees because everyone works on a contractual basis, and the original agreements are with the two hedge funds who are financing the entire operation. This situation should change in the next few months with the set up and installation of the laboratory.
At the time of the acquisition of the licenses, the Company immediately created a deficit of more than $50 million by depreciating the value of those. In order to answer this recurring issue, the board of directors made this decision to avoid an over evaluation of the Company before it starts generating significant revenues. An independent third party evaluation by a specialized biotech firm is planned by management to assess the Company's assets and make a subsequent move onto a more important exchange. The evaluation by an independent firm specialized in biotech of the Company's assets will be planned when the direction will decide that the Company is in a position to upgrade to a more important exchange.
The Company would also like to point out that for its market penetration plans, Neuro-Biotech is also using the conclusions of a report ordered to the firm Ernst & Young (Toronto) concerning the potential market of its products.
The negotiations with the Spaniards are moving forward and the Company is preparing for two tours in Spain for 2011 with a group of representatives. Both tours will be separate and completely independent as one will be of scientific content while the other one will be focused on the commercial aspects. These tours will probably extend throughout Europe since the Company recently received similar proposals from Germany.
Finally, the Company foresees the receipt of the private placement of $2 million as well as full payment of the debt owed to third parties before the end of this year.
For more information and to view the documents describing the key elements mentioned above, we invite you visit the corporate website at www.neuro-biotechcorp.com. Details can be found in the Mission Section: 'A Brief History'. A direct link is also on the Home page of the website.
BASEL, Switzerland, February 8, 2011 / CNW Telbec / -- Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB: MRES), having recently signed a Business Development Agreement with Russian based Credo-TM, who in turn had just finished negotiations for 1,000,000 Post Traumatic Stress Disorder (PTSD) test with their nation?s military forces to help with early detection of PTSD which is an ongoing concern for worldwide military forces.
Stress, as defined by Hans Selye in 1945, could be expressed in regards to active military people first as a physical stress - we know that active military people are trained to be able to physically react to specific situations. Second, it can be expressed as a mental stress - active military people are also well trained in regards to alertness, vigilance, attention or automatisms related to their equipments. Finally, it can also be expressed in the form of emotional stress - it is the link to work with PTSD.
The human emotional memory is the basis of PTSD. In fact, the brain is used to receive all kind of information through our five senses, to retain and integrate it, to remember and initiate the emotions through "FLASHBACKS". In PTSD, such emotional information is so strong that it is impossible to forget it. However, it is possible to manage with it through recognition and acceptation process.
Some statistical data have clearly demonstrated that PTSD is present in the population. Thus, in USA, 5,600,000 people are affected, 1,600,000 in Germany, 1,200,000 in France, 1,600,000 in Egypt while in Switzerland, less than 200,000 people are affected by PTSD. These data are in good correlation with the WHO saying in its 2000?s Report that "Stress - a century?s disease".
Neuro-Biotech Licensees Network: LOI with Israel
Tuesday 25, January 2011
Neuro-Biotech Pursues the Implementation of its Licensees Network and Signs a LOI with Israel
BASEL, Switzerland, Jan. 25 - Neuro-Biotech Corp. (MRES-OTCQB) is pleased to announce the signing of a Letter of Intent with a major distributor in Israel.
Both groups are discussing the details of a Licensing Agreement based on similar terms and conditions as the recently negotiated agreement with the Russian company Credo-TM.
Furthermore, Neuro-Biotech intends to contract the manufacturing of the tests ordered by its Licensee in Israel and to that effect discussions have already taken place with Sigma-Aldrich a renowned pharmaceutical firm in Israel.
With the signing of this Letter of Intent with the Israelis, Neuro-Biotech gains a strong foothold and is able to pursue in an accelerated way the implementation of its Licensee network throughout the world. This allows the Company to initiate the next phase of its development plan namely the creation of its own "Technological Showcase" to support the training of technicians and the development of new products.
Credo-TM purchased of a 275 M USD agreement for revolutionary Neuro Science Technology
17.01.2011, 12:21
Credo-TM Corporation proudly announces that it has signed an agreement with Neuro-Biotech Corp (OTCQB-MRES) a corporation with a strong expertise in the neuro science field. The agreement provides that Credo-TM Corporation acquires the exclusive rights to distribute all the licensed blood tests and Neuroceuticals? in Russia, Belarus, Ukraine and Kazakhstan. Moreover Credo-TM Corporation will receive all the knowhow for the analysis of the blood tests as well as the right to participate in all new research.
These unique blood tests can determine on an objective scale the level of stress and depression of the brain. Among the other tests, there are some which can provide an early diagnostic of neuro-related diseases such as Alzheimer.
These tests will help significantly reduce the expenditures devoted on these various diseases.
ABOUT NEURO-BIOTECH CORPORATION
Neuro-Biotech Corp. (www.neuro-biotechcorp.com) is a public neuroscience medical diagnostic enterprise, based in Basel (Switzerland), and is the first neuro-pharmaceutical company to bring to market analytical diagnostic products specifically designed to facilitate early diagnosis, and monitoring of neuro degenerative diseases. This will allow follow-up treatments, through a targeted therapeutic approach to the major psycho-social environmental diseases related to the neuro-psycho-endocrine and immune systems.
Announcement: First Exclusive License Agreement with Credo-TM for Distribution in the Russian Federation
Tuesday 18, January 2011
NEURO-BIOTECH CORP. ANNOUNCES THE SIGNING OF ITS FIRST EXCLUSIVE LICENSE AGREEMENT WITH CREDO-TM CORP. FOR DISTRIBUTION OF ITS PRODUCTS IN THE RUSSIAN FEDERATION
BASEL, Switzerland, jan. 18, 2011, Neuro-Biotech Corp. (OTCQB: MRES) announces that it has concluded a Business Development Agreement with Credo-TM, a Russian company.
The Agreement provides for an exclusive right to distribute all Neuro-Biotech proprietary blood analysis kits and NeuroCeuticals™ in territories such as Russia, Belarus, Ukraine and Kazakhstan. Furthermore this agreement binds Credo-TM to a minimum yearly order of 500,000 test units for a term of 10 years. Both parties have agreed on an initial price of $55.00 USD per unit for its initial launch. The pricing for subsequent years may be subject to change.
Over the next three month, Credo-TM will be selecting the laboratories mandated to undertake the tests analysis. Neuro-Biotech will be overseeing the technician training program for protocol analysis application.
ABOUT CREDO-TM
Credo-TM, a private entity, was created by a group of professors and doctors from one of Russia's oldest and largest human physiological health laboratory. The company is based in the Techno Park area of Kazan City in the Russian Federation. Over the past several years Credo-TM has developed, with the help of government grants, a solid distribution network of advanced and modern medical products in countries such as Russia, Belarus, Ukraine and Kazakhstan. Close to 1200 medical centers and hospitals are using the services of Credo-TM today. The Company's initial effort was the distribution of diagnostic tests for diabetes, pregnancy as well as tuberculosis (early stage). Over the past 3 years, more than 300 employees have joined Credo-TM.
Phone: +7 (843) 272-89-24 - Business Hours: 9-17 (Local Time)
Announcement: Neuro-Biotech, Now reached Dept Free Status
Tuesday 14, December 2010
NEURO-BIOTECH CORP. ANNOUNCES, HAVING NOW REACHED DEBT FREE STATUS, AND CURRENTLY PLANNING ITS DISTRIBUTION PROGRAM FOR 2011
BASEL, Switzerland, le 14 déc. - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) announced today having now reached debt free status, and currently planning its distribution program for 2011.
After 2 years of hard work and administrative organisation to finance and bring to market the distribution of its products, Neuro-Biotech Corp. is proud to inform its shareholders that it has repaid all debts to third parties totalling the sum of one million, one hundred, twenty five thousand and nine hundred thirteen dollars ($ 1,125,913).
"The team has been working non-stop to attain this level, and we now have all green lights to begin a strategically planned series of Scientific Speakerships and Road Shows in Europe and United States."
For more information on Neuro-Biotech Products: neuro-biotechcorp.com.
Was thinking the same thing JD, just don't understand why the price isn't creeping up
Thanks Brother...It is getting tougher to comprehend the immensity of this. Have you gained any more insight in the past couple of days? Looking at buying more today, I have no idea what's going to happen next week!
Far as I have seen, Guarddogs OS is the Float
Choi, this SeaWind Marine is the same SeaWind? Crazy stuff, nice find.
Can you tell me where you found this, would like to read more.
"The Boatbuilding and Fabrication facilities are based in Appledore, North Devon, where the company draws upon its long term multi-skilled workforce and modern production facility to offer a wide range of marine related engineering and fabrication services to customers requiring a quality product delivered professionally, efficiently and on time."
Haha.. much more politically correct then the earlier post...lol
Did I research it? Other than it being maxed, no...But I guess I am the only one that thinks that it's a potential possible problem...Hoping for the best, not bashing, just inquiring... Just bought in a few days ago...remarkable PR and we close down? I know how this works, don't post anything that shines a negative light on the company...blah blah blah
Or, increase AS or do a reverse split... research that
How is the 1Billion A/S O/S helping us?
you just seem to miss the forest of shares
And todays performance proves that???
Just called IR for that very reason...No Answer
The AS is topped out at 1 Billion... What do you think it should be trading at?
Good times!!! nearly doubled the OS...
Didn't consider that, good point
Nearly $10,000 at this stage, have you learned anything from IR?? We have been dropping in price for the last 6 months and we have seen nothing but dilution and learned that we can't count on Watson or the company to stick to their word... Would be very surprised (still hopeful though) to see anything positive at the end on the month.
The 10 million a day really says the dilution is continuing...
new here, looking at buying...love the chart...are you projecting .15 just because of 1 oil well rig? Are there any other Rigs or streams of income... What are the reasons for .15 Thanks
Thanks Brother...What is your estimated value of the merger? possible share price?
So the rumours of 4 billion going to 3power are most likely bogus
I have never been apart of a buyout before...simply asking questions...If they have accepted .15 and sold the company, just curious how it could trade like a regular stock at .02
You may have to inform the "Real World" ...
Hope you get all the shares you are trying for.
So can we still be apart of the .15 if we buy-in in the morning?? Can we still trade and flip this?